Eli Lilly ended 2019 with a win in its long-running legal battle to prevent generics of its big-selling cancer drug Alimta from reaching the US market. The ruling came in a dispute with Canadian ...
Lilly's cancer drug Alimta is to face early generic competition in several European countries after a UK court ruling. The English High Court has ruled that the vitamin dosage regimen patents for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback